Immunoregulatory effect of artesunate on allergic contact dermatitis and its mechanism

Yaoxue Xuebao

Volumn 47, Issue 7, 2012, Pages 884-889

  Li, Tan ^a   Chen, Hong ^a   Liu, Xiao Guang ^a   Zhou, Ya Xun ^a   Bai, Shu Fang ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Allergic contact dermatitis; Artesunate; Immunologic balance; NF B

Indexed keywords

ARTESUNATE; GAMMA INTERFERON; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR T BET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; DRUG MECHANISM; IMMUNOREGULATION; INFLAMMATORY CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN ALLERGY; SWELLING; TOPICAL TREATMENT; WESTERN BLOTTING;

ADMINISTRATION, TOPICAL; ANIMALS; ARTEMISININS; DERMATITIS, ALLERGIC CONTACT; EAR; FEMALE; GATA3 TRANSCRIPTION FACTOR; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; NF-KAPPA B; RNA, MESSENGER; T-BOX DOMAIN PROTEINS;

EID: 84866118225     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention [J]. J Am Acad Dermatol, 2005, 53: 845.
2. Zhang JX, Wang JX, Zhang Y, et al. Synthesis and immuno-suppressive activity of new artemisinin derivatives containing polyethylene glycol group [J]. Acta Pharm Sin, 2006, 41: 65-70.
3. Hirasaki Y, Iwamura C, Yamashita M, et al. Repressor of GATA negatively regulates murine contact hypersensitivity through the inhibition of type-2 allergic responses [J]. Clin Immunol, 2011, 139: 267-276.
4. Bowen H, Kelly A, Lee T, et al. Control of cytokine gene transcription in Th1 and Th2 cells [J]. Clin Exp Allergy, 2008, 38: 1422-1431.
5. Jenner RG, Townsend MJ, Jackson I, et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes [J]. Proc Natl Acad Sci USA, 2009, 106: 17876-17881.
6. Ramacher M, Umansky V, Efferth T. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model [J]. Anticancer Drugs, 2009, 20: 910-917.
7. Li B, Li J, Pan X, et al. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation [J]. Int Immunopharmacol, 2010, 10: 344-350.
8. Li Y, Wu YL. An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional Chinese herb [J]. Curr Med Chem, 2003, 10: 2197-2230.
9. Westphal GA, Schnuch A, Moessner R, el al. Cytokine gene polymorphisms in allergic contact dermatitis [J]. Contact Dermatitis, 2003, 48: 93-98.
10. Frenzel DF, Weiss JM. Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy [J]. Expert Rev Clin Immunol, 2011, 7: 93-109.
11. Biedermann T, Mailhammer R, Mai A, et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen specific Th2 cells [J]. Eur J Immunol, 2001, 31: 1582-1591.
12. Hwang ES, Szabo SJ, Schwartzberg PL, et al. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3 [J]. Science, 2005, 307: 430-433.
13. Pande V, Ramos MJ. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors [J]. Curr Med Chem, 2005, 12: 357-374.
14. Cho YC, Lee SH, Yoon G, et al. Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappa B [J]. Int Immunopharmacol, 2010, 10: 1119-1126.
15. 4 [J]. J Immunol, 2010, 185: 89-98.
16. Yang ZB, Yang CH, Gao Y. Immunomodulatory mechanisms of artesunate in TNBS-induced colitis in mice [J]. Chin J Gastroenterol, 2010, 15: 143-146.